中华行为医学与脑科学杂志
中華行為醫學與腦科學雜誌
중화행위의학여뇌과학잡지
CHINESE JOURNAL OF BEHAVIORAL MEDICINE AND BRAIN SCIENCE
2011年
6期
541-544
,共4页
王贵山%张传芝%高蕾%王爱芹%王秋玲%姚宁
王貴山%張傳芝%高蕾%王愛芹%王鞦玲%姚寧
왕귀산%장전지%고뢰%왕애근%왕추령%요저
盐酸曲唑酮%酒依赖%戒断%心理及生理症状%复饮
鹽痠麯唑酮%酒依賴%戒斷%心理及生理癥狀%複飲
염산곡서동%주의뢰%계단%심리급생리증상%복음
Trazodone%Alcohol dependence%Withdrawal%The symptoms of physical and psychological%Recovery drink
目的 探讨盐酸曲唑酮治疗酒依赖戒断后患者焦虑、抑郁、失眠等心理及躯体症状的有效性和安全性.方法 采用随机、双盲、安慰剂对照的方法把100例符合纳入和排除标准的患者分成盐酸曲唑酮组和安慰剂组.每个患者均口服盐酸曲唑酮或安慰剂每日3次,每次1片,疗程均为8周.于治疗后第l,2,4,8周末分别进行汉密顿焦虑量表(HAMA)、汉密顿抑郁量表(HAMD)、匹兹堡睡眠质量指数(PSQI)、副反应量表(TESS)评分.1年后调查复饮情况.结果 有81例完成治疗,19例因提前出院或失访未完成治疗脱失.盐酸曲唑酮组(41例)汉密顿焦虑量表、汉密顿抑郁量表及匹兹堡睡眠质量指数评分治疗后与治疗前比较,总分值逐渐下降,2周后上述3项评分和安慰剂组(40例)分别比较差异有显著性(P<0.05);1年后复饮率盐酸曲唑酮组(24.4%)明显低于安慰剂组(55.0%,P<0.05).治疗后两组副反应量表评分比较差异无显著性(P>0.05).结论 盐酸曲唑酮能有效改善酒依赖戒断后患者焦虑、抑郁及失眠症状,且能有效降低复饮率.
目的 探討鹽痠麯唑酮治療酒依賴戒斷後患者焦慮、抑鬱、失眠等心理及軀體癥狀的有效性和安全性.方法 採用隨機、雙盲、安慰劑對照的方法把100例符閤納入和排除標準的患者分成鹽痠麯唑酮組和安慰劑組.每箇患者均口服鹽痠麯唑酮或安慰劑每日3次,每次1片,療程均為8週.于治療後第l,2,4,8週末分彆進行漢密頓焦慮量錶(HAMA)、漢密頓抑鬱量錶(HAMD)、匹玆堡睡眠質量指數(PSQI)、副反應量錶(TESS)評分.1年後調查複飲情況.結果 有81例完成治療,19例因提前齣院或失訪未完成治療脫失.鹽痠麯唑酮組(41例)漢密頓焦慮量錶、漢密頓抑鬱量錶及匹玆堡睡眠質量指數評分治療後與治療前比較,總分值逐漸下降,2週後上述3項評分和安慰劑組(40例)分彆比較差異有顯著性(P<0.05);1年後複飲率鹽痠麯唑酮組(24.4%)明顯低于安慰劑組(55.0%,P<0.05).治療後兩組副反應量錶評分比較差異無顯著性(P>0.05).結論 鹽痠麯唑酮能有效改善酒依賴戒斷後患者焦慮、抑鬱及失眠癥狀,且能有效降低複飲率.
목적 탐토염산곡서동치료주의뢰계단후환자초필、억욱、실면등심리급구체증상적유효성화안전성.방법 채용수궤、쌍맹、안위제대조적방법파100례부합납입화배제표준적환자분성염산곡서동조화안위제조.매개환자균구복염산곡서동혹안위제매일3차,매차1편,료정균위8주.우치료후제l,2,4,8주말분별진행한밀돈초필량표(HAMA)、한밀돈억욱량표(HAMD)、필자보수면질량지수(PSQI)、부반응량표(TESS)평분.1년후조사복음정황.결과 유81례완성치료,19례인제전출원혹실방미완성치료탈실.염산곡서동조(41례)한밀돈초필량표、한밀돈억욱량표급필자보수면질량지수평분치료후여치료전비교,총분치축점하강,2주후상술3항평분화안위제조(40례)분별비교차이유현저성(P<0.05);1년후복음솔염산곡서동조(24.4%)명현저우안위제조(55.0%,P<0.05).치료후량조부반응량표평분비교차이무현저성(P>0.05).결론 염산곡서동능유효개선주의뢰계단후환자초필、억욱급실면증상,차능유효강저복음솔.
Objective To explore the efficacy and safety of anxiety, depression, insomnia and other psychological and physical symptoms after trazodone treated in patients with alcohol dependence. Methods 100 patients whose met the inclusion and exclusion criteria were divided into trazodone group and the placebo group with a randomized, double-blind, placebo-controlled method. Each of the patients was oral trazodone, or placebo 3 times a day, each time a course of treatment was 8 weeks. Hamilton Anxiety Scale ( HAM A) , Hamilton Depression Rating Scale(HAMD) , Pittsburgh Sleep Quality Index(PSQI) , side effects scale (TESS) score and the necessary examinations were used to assess. Survey the re-drink situation after 1 year. Results 81 patients completed treatment, 19 patients were discharged or lost due to early treatment failure loss. In Trazodone group (41 cases) , the HAMA, HAMD and PSQI score before treatment and after treatment, total scores decreased gradually after 2 weeks of the three score and comfort dose group (40 cases) were the difference was statistically significant (P< 0. 05 ) ;recovery drink rate of trazodone group was significantly lower than the placebo group (24.4% vs 55. 0% , P<0. 05) after 1 year. After treatment, the side effects scale score difference was not statistically significant (P> 0. 05 ). Conclusion Improve trazodone treat alcohol dependence withdrawal anxiety, depression and insomnia effectively. Found no adverse drug reactions and the safety is high. Reduce the recovery drink.